Huntington's Disease Center Publications

Plasma NfL as a prognostic biomarker for enriching HD-ISS stage 1 categorisation: a cross-sectional study.

Parkin GM, Thomas EA, Corey-Bloom J.  E BioMedicine. 2023 Jun 12;93:104646. 

Graphomotor Dysfluency as a Predictor of Disease Progression in Premanifest Huntington's Disease.

Caligiuri M, Culbert B, Prasad N, Snell C, Hall A, Smirnova A, Churchill E, Corey-Bloom J. J Huntingtons Dis. 2023 May 8. 

Anosognosia in HD: Comparison of self-report and caregiver ratings with objective performance measures.

Hughes SB, Churchill E, Smirnova A, Hall A, Culbert B, Snell C, Wright BA, Gilbert PE, Corey-Bloom J. Parkinsonism Relat Disord. 2023 Feb;107:105272. 

Development and Psychometric Properties of a New Brief, Yet Comprehensive, Behavioral Questionnaire for Huntington's Disease.

Hughes S, Aboufadel S, Smirnova A, Snell C, Churchill E, Hall A, Malcarne V, Gilbert PE, Corey-Bloom J. Mov Disord Clin Pract. 2023 Feb 2;10(3):427-433. 

Salivary Huntingtin protein is uniquely associated with clinical features of Huntington's disease.

Parkin GM, Corey-Bloom J, Snell C, Smith H, Laurenza A, Daldin M, Bresciani A,    Thomas EA. Sci Rep. 2023 Jan 19;13(1):1034. 

Associations between prognostic index scores and plasma neurofilament light in Huntington's disease.

Parkin GM, Corey-Bloom J, Long JD, Snell C, Smith H, Thomas EA. Parkinsonism Relat Disord. 2022 Apr;97: 25-28.

Source recognition discriminability impairment in Huntington's versus Alzheimer's disease: Evidence from the CVLT-3.

Graves LV, Churchill EG, Williams ME, Van Etten EJ, Bondi MW, Salmon DP, Corey-Bloom J, Delis DC, Gilbert PE. Appl Neuropsychol Adult. 2022 Aug 19:1-6.

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.

Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M.; Huntington Study Group SIGNAL investigators. Nat Med. 2022 Oct; 28(10):2183-2193.

The Repeatable Battery for the Assessment of Neuropsychological Status, While Useful for Measuring Cognitive Changes in Manifest Huntington Disease, May Show Limited Utility in Premanifest Disease.

Mustafa AI, Corey-Bloom J, Beltran-Najera I, Snell C, Castleton J, Smith H, Gilbert PE.  Cogn Behav Neurol. 2022 Sep 1;35(3):198-203.

Differences in body sway can be identified in Huntington's disease using a practical balance assessment device.

Mustafa AI, Corey-Bloom J, Howell S, Gilbert PE, Goble DJ. Parkinsonism Relat Disord. 2022 Oct;103:115-118. 

Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression.

Parkin GM, Corey-Bloom J, Snell C, Castleton J, Thomas EA. Parkinsonism Relat Disord. 2021 Jun; 87:32-38.

Revisiting total recognition discriminability in Huntington's and Alzheimer's disease: new insights from the CVLT-3.

Graves LV, Simone S, Williams M, Courville T, Mattson SN, Delano-Wood L, Bondi MW, Salmon DP, Corey-Bloom J, Delis DC, Gilbert PE. Appl Neuropsychol Adult. 2021 Mar-Apr;28(2):132-139.

Central Cognitive Processing Speed Is an Early Marker of Huntington's Disease Onset.

Corey-Bloom J, Williams ME, Beltran-Najera I, Mustafa AI, Snell CM, Castleton J, Smith H, Wright B, Gilbert PE. Mov Disord Clin Pract. 2020 Dec 28;8(1):100-105.

Genotyping Single Nucleotide Polymorphisms for Allele-Sensitive Therapy in Huntington's Disease
Classen DO, Corey-Bloom J, Dorsey ER, Edmondson M, Kostyk SK, LeDoux MS, Reilmann R, Rosas HD, Walker F, Wheelock V, Svrzikapa N, Longo KA, Goyal J, Hung S, Panzara MA. Neurol Genet. 2020 May 14;6(3):e430.

The Emergence of Age-Related Changes in Recognition Memory in healthy Middle-Aged Adults Using the CVLT-II
Williams ME, Graves LV, Van Etten EJ, Holden HM, Delano-Wood L, Bondi MW, Corey-Bloom J, Delis DC, Gilbert PE. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2020 Nov;27(6):854-863.

Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington's Patients
Corey-Bloom J, Haque A, Aboufadel S, Snell C, Fischer RS, Granger SW, Granger DA, Thomas EA. Front Neurosci. 2020 Mar 4;14:73

Central Cognitive Processing Speed is an Early Marker of Huntington's Disease Onset
Corey-Bloom J, Williams ME, Beltran-Najera I, Mustafa AI, Snell CM, Castelton J, Smith H, Wright B, Gilbert PE. Mov Disord Clin Pract. 2020 Dec 28;8(1):100-105.

Identification of Subtle Verbal memory Deficits in Premanifest Huntington's Disease Using the California Verbal Learning Test 
Holden HM, Tierney SM, Graves LV, Beltran-Najera I, Woods SP, Snell CM, Delis DC, Corey-Bloom J, Gilbert PE. Cogn Behav Neurol. 2020 Mar;33(1):16-22.

Levels of Interleukin-6 in Saliva, but Not Plasma, Correlate with Clinical Metrics in Huntington's Disease Patients and Healthy Control Subjects
Corey-Bloom J, Fischer RS, Kim A, Snell C, Parkin GM, Granger DA, Granger SW, Thomas EA. Int J Mol Sci. 2020 Sep 2;21(17):6363.

Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington's Disease Patients
Gutierrez A, Corey-Bloom J, Thomas EA, Desplats P. Front Mol Neurosci. 2020 Jan 23;12:335.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study 
Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019 Feb;18(2):165-176.

Handwriting Movement Abnormalities in Symptomatic and Premanifest Huntington's Disease 
Caligiuri M, Snell C, Park S, Corey-Bloom J. Mov Disord Clin Pract. 2019 Aug 16;6(7):586-592.

Medication Management Capacity and Its Neurocognitive Correlates in Huntington's Disease 
Sumida CA, Van Etten EJ, Lopez FV, Sheppard DP, Priogovsky-Turk E, Corey-Bloom J, Filoteo JV, Woods SP, Gilbert PE, Schmitter-Edgecombe M. Arch Clin Neuropsychol. 2019 Oct 24;34(7):1121-1126.

Recall and Recognition Discriminability in Parkinson's Disease and Huntington's Disease 
Van Etten EJ, Graves LV, Taylor B, Holden HM, Lopez FV, Williams ME, Pirogovsky-Turk E, Corey-Bloom J, Filoteo JV, Delis DC, Gilbert PE. J Huntington's Dis. 2019;8(4):459-465.

Revisiting Total Recognition Discriminability in Huntington's and Alzheimer's Disease: New Insights from the CVLT-3 
Graves LV, Simone S, Williams M, Courville T, Mattson SN, Dewlano-Wood L, Bondi MW, Salmon DP, Corey-Bloom J, Delis DC, Gilbert PE. Appl Neuropsychol Adult. 2019 May 6:1-8

New Intrusion Analyses on the CVLT-3: Utility in Distinguishing the Memory Disorders of Alzheimer's versus Huntington's Disease 
Graves LV, Holden HM, Van Etten EJ, Delano-Wood L, Bondi MW, Salmon DP, Corey-Bloom J, Gilbert PE, Delis DC. J Int Neuropsychol Soc. 2019 Sep;25(8):878-883

Verbal Episodic Memory profiles in HIV-Associated Neurocognitive Disorders (Hand): A Comparison with Huntington's Disease and Mesial Temporal Lobe Epilepsy 
Doyle KL, Woods SP, McDonald CR, Leyden KM, Holden HM, E Morgan E, Gilbert PE, Corey-Bloom J. Appl Neurospychol Adult. 2019 Jan-Feb; 26(1):17-27.

Medication Management Capacity and Its Neurocognitive Correlates in Huntington’s Disease
Sumida CA, Van Etten EJ, Lopez FV, Sheppard DP, Pirogovsky-Turk E, Corey-Bloom J, Filoteo JV, Woods SP, Gilbert PE, Schmitter-Edgecombe M. Medication Management Capacity and Its Neurocognitive Correlates in Huntington's Disease. Arch Clin Neuropsychol. 2018 Dec 5.

New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease.
Graves LV, Holden HM, Van Etten EJ, Delano-Wood L, Bondi MW, Salmon DP, Corey-Bloom J, Delis DC, Gilbert PE. New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc. 2018 Sep;24(8):833-841.

Salivary levels of total huntingtin are elevated in Huntington’s disease patients
Corey-Bloom J, Haque AS, Park S, Nathan AS, Baker RW, Thomas EA. Salivary levels of total huntingtin are elevated in Huntington's disease patients. Sci Rep. 2018 May 9;8(1):7371.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017 Dec 12;89(24):2495-2502.

Graves LV, Van Etten EJ, Holden HM, Delano-Wood L, Bondi MW, Corey-Bloom J, Delis DC, Gilbert PE. Refining CVLT-II recognition discriminability indices to enhance the characterization of recognition memory changes in healthy aging. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2018 Sep;25(5):767-782.

Doyle KL, Woods SP, McDonald CR, Leyden KM, Holden HM, E Morgan E, Gilbert PE, Corey-Bloom J. Verbal episodic memory profiles in HIV-Associated Neurocognitive Disorders (HAND): A comparison with Huntington's disease and mesial temporal lobe epilepsy. Appl Neuropsychol Adult. 2017 Aug 29:1-11.

Corey-Bloom J, Aikin AM, Gutierrez AM, Nadhem JS, Howell TL, Thomas EA. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017 Oct 15;1673:102-110.

Van Liew C, Santoro MS, Goldstein J, Gluhm S, Gilbert PE, Corey-Bloom J. Evaluating Recall and Recognition Memory Using the Montreal Cognitive Assessment: Applicability for Alzheimer's and Huntington's Diseases. Am J Alzheimers Dis Other Demen. 2016 Dec;31(8):658-663.

Graves LV, Holden HM, Delano-Wood L, Bondi MW, Woods SP, Corey-Bloom J, Salmon DP, Delis DC, Gilbert PE. Total recognition discriminability in Huntington's and Alzheimer's disease. J Clin Exp Neuropsychol. 2017 Mar;39(2):120-130.

Sheppard DP, Pirogovsky-Turk E, Woods SP, Holden HM, Nicoll DR, Filoteo JV, Corey-Bloom J, Gilbert PE. Everyday Functioning in Huntington's Disease: A Laboratory-Based Study of Financial Management Capacity. Appl Neuropsychol Adult. 2017 Mar-Apr;24(2):176-182.

Corey-Bloom J, Gluhm S, Herndon A, Haque AS, Park S, Gilbert PE. Benton Judgment of Line Orientation (JoLO) Test: A Brief and Useful Measure for Assessing Visuospatial Abilities in Manifest, but not Premanifest, Huntington's Disease. J Huntingtons Dis. 2016;5(1):91-6.

Huntington Study Group PHAROS Investigators., Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan;73(1):102-10.

Pirogovsky E, Nicoll DR, Challener DM, Breen E, Gluhm S, Corey-Bloom J, Gilbert PE. The Visual Spatial Learning Test: Differential impairment during the premanifest and manifest stages of Huntington's disease. J Neuropsychol. 2015 Mar;9(1):77-86.

Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015 Jan;14(1):39-47.

Corey-Bloom J, Jia H, Aikin AM, Thomas EA. Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease. J Huntingtons Dis. 2014;3(3):311-6.

Hall CA, Reynolds CF 3rd, Butters M, Zisook S, Simon N, Corey-Bloom J, Lebowitz BD, Begley A, Mauro C, Shear MK. Cognitive functioning in complicated grief. J Psychiatr Res. 2014 Nov;58:20-5.

Nicoll DR, Pirogovsky E, Woods SP, Holden HM, Filoteo JV, Gluhm S, Corey-Bloom J, Gilbert PE. "Forgetting to remember" in Huntington's disease: a study of laboratory, semi-naturalistic, and self-perceptions of prospective memory. J Int Neuropsychol Soc. 2014 Feb;20(2):192-9

Pirogovsky E, Nicoll DR, Challener DM, Breen E, Gluhm S, Corey-Bloom J, Gilbert PE. The Visual Spatial Learning Test: Differential impairment during the premanifest and manifest stages of Huntington's disease. Pirogovsky E, Nicoll DR, Challener DM, Breen E, Gluhm S, Corey-Bloom J, Gilbert PE. J Neuropsychol. 2013 Dec 11.

Van Liew C, Gluhm S, Goldstein J, Cronan TA, Corey-Bloom J. The functional implications of motor, cognitive, psychiatric, and social problem-solving states in Huntington's disease. Psychiatry. 2013 Winter;76(4):323-35.

Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AF, Biglan KM, Shoulson I; Huntington Study Group COHORT Investigators. Natural history of Huntington disease. JAMA Neurol. 2013 Dec;70(12):1520-30.

Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol. 2013 Nov;70(11):1382-8.

Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord. 2013 Sep;28(10):1407-15.

Gluhm S, Goldstein J, Brown D, Van Liew C, Gilbert PE, Corey-Bloom J. Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease. Mov Disord. 2013 Jun 24. doi: 10.1002/mds.25578. [Epub ahead of print]

Gluhm S, Goldstein J, Loc K, Colt A, Liew CV, Corey-Bloom J. Cognitive performance on the mini-mental state examination and the montreal cognitive assessment across the healthy adult lifespan. Cogn Behav Neurol. 2013 Mar;26(1):1-5.

Mickes L, Wixted JT, Peavy GM, Jacobson MW, Goldstein JL, Corey-Bloom J. Difficulty modifying a sustained motor response in prodromal Huntington's disease. J Clin Exp Neuropsychol. 2013;35(1):35-40.

Cloud LJ, Rosenblatt A, Margolis RL, Ross CA, Pillai JA, Corey-Bloom J, Tully HM, Bird T, Panegyres PK, Nichter CA, Higgins DS Jr, Helmers SL, Factor SA, Jones R, Testa CM. Seizures in juvenile Huntington's disease: Frequency and characterization in a multicenter cohort. Mov Disord. 2012 Dec;27(14):1797-800.

Pillai JA, Hansen LA, Masliah E, Goldstein JL, Edland SD, Corey-Bloom J. Clinical severity of Huntington's disease does not always correlate with neuropathologic stage. Mov Disord. 2012 Aug;27(9):1099-103.

Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2012 Jun;83(6):612-9.

Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. 8OHdG as a marker for Huntington disease progression. Neurobiol Dis. 2012 Jun;46(3):625-34. Epub 2012 Mar 5.

Dorsey ER; Huntington Study Group COHORT Investigators. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS One. 2012;7(2):e29522.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012 Mar 6;78(10):690-5.

Majid DS Adnan, BS, Aron Adam R, PhD, Thompson Wesley, PhD, Sheldon Sarah, BS, Hamza Samar, BS, Stoffers Diederick, PhD, Holland Dominic, PhD, Goldstein Jody, BS, Corey-Bloom Jody, MD, PhD, and Dale Anders M., PhD. Basal Ganglia Atrophy in Prodromal Huntington’s Disease Is Detectable Over One Year Using Automated Segmentation. Movement Disorders, 2011 Vol. 000, No. 000, 0000.

Turner TH, Goldstein J, Hamilton JM, Jacobson M, Pirogovsky E, Peavy G, Corey-Bloom J. Behavioral Measures of Saccade Latency and Inhibition in Manifest and Premanifest Huntington's Disease. J Mot Behav. 2011 Jul-Aug;43(4):295-302. Epub 2011 Jun 24

Majid DS, Stoffers D, Sheldon S, Hamza S, Thompson WK, Goldstein J, Corey-Bloom J, AronAR. (2011). Automated Structural Imaging Analysis Detects Premanifest Huntington’s Disease Neurodegeneration Within 1 Year. Movement Disorders , 2011 Apr 11. doi: 10.1002/mds.23656. [Epub ahead of print]

Rizk-Jackson A, Stoffers D, Sheldon S, Kuperman J, Dale A, Goldstein J, Corey-Bloom J, Poldrack RA, Aron AR. Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques. Neuroimage. 2011 May 15;56(2):788-96.

Robert Panzera, Danielle Salomonczyk, Eva Pirogovsky, Roger Simmons, Jody Goldstein, Jody Corey-Bloom, Paul Gilbert. Postural deficits in Huntington’s disease when performing motor skills involved in daily living. Gait Posture. 2011 Mar;33(3):457-61. Epub 2011 Jan 20.

Salomonczyk D, Panzera R, Pirogovosky E, Goldstein J, Corey-Bloom J, Simmons R, Gilbert PE. Impaired postural stability as a marker of premanifest Huntington's disease.  Mov Disord. 2010 Oct 30;25(14):2428-33.

Mickes L, Jacobson M, Peavy G, Wixted JT, Lessig S, Goldstein JL, Corey-Bloom, J. A Comparison of Two Brief Screening Measures of Cognitive Impairment in Huntington’s Disease. Movement Disorders, 2010 Oct 15;25(13):2229-33.

Quaid KA, Swenson MM, Sims SL, Harrison JM, Moskowitz C, Stepanov N, Suter GW, Westphal BJ; Huntington Study Group PHAROS Investigators and Coordinators. What were you thinking?: individuals at risk for Huntington Disease talk about having children. J Genet Couns. 2010 Dec;19(6):606-17. Epub 2010 Aug 24.

Stoffers D, Sheldon S, Kuperman, JM, Goldstein, J, Corey-Bloom, J, Aron, AR. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology. 2010 Apr 13;74(15):1208-16.

Guerry M. Peavy, PhD, Mark W. Jacobson, PhD, Jody L. Goldstein, BS, Joanne M. Hamilton, PhD, Amy Kane, MS, Anthony C. Gamst, PhD, Stephanie L. Lessig, MD, J. C. Lee, BA, and Jody Corey-Bloom, MD, PhD. Cognitive and Functional Decline in Huntington’s Disease: Dementia Criteria Revisited. Movement Disorders , Mov Disord. 2010 Jul 15;25(9):1163-9.

Fine, EM, Delis DC, Wetter, SR, Jacobson, MW, Hamilton, JM, Peavy, G, Goldstein, J, McDonald, C, Corey-Bloom, J, Bondi, MW & Salmon, DP.  Identifying the "Source" of Recognition Memory Deficits in Patients With Huntington's Disease or Alzheimer's Disease.  Journal of Clinical and Experimental Neuropsychology, Volume 30 (4), 463-470.

Ho ML, Loc K, Goldstein JL, Peavy GM, Jacobson MW, Lessig S, Corey-Bloom J (2008).  MoCA vs MMSE:  Patterns of Cognitive Performance By Decade In Community-Dwelling Healthy Adults.  Submitted for the 133rd Annual Meeting American Neurological Association.

Lessig S, Ho ML, Jacobson MW, Peavy G, Goldstein JL, Kim RY, Wetzel K, Fontaine D, Corey-Bloom J (2008).  A Comparison of Two Brief Cognitive Screening Instruments in Parkinson’s Disease.  Presented at the 60th Annual Meeting of the American Academy of Neurology (Chicago, IL).

Lessig S, Ho ML, Jacobson MW, Peavy G, Goldstein JL, Lee A, Loc K, Corey-Bloom J (2008).  A Comparison Of Two Brief Cognitive Measures In Parkinson’s Disease (PD).  Presented at the 12th International Congress of Parkinson’s Disease and Movement Disorders (Chicago, IL).

Mickes L, Cane AE, Jacobson MW, Peavy G, Goldstein JL, Lessig S., Kim RY, Di Toro BM, Fine E. Corey-Bloom J (2007).  A Comparison of Two Brief Cognitive Screening Instruments in Huntington’s Disease (HD). Inaugural HD Clinical Research Symposium.

Mickes L, Jacobson MW, Peavy G, Goldstein JL, Ho ML, Lessig S, Kim RY, Civilini M, Loc K, Corey-Bloom J (2008).  Screening for Cognitive Impairment in Individuals with and at Risk for Huntington’s Disease. Presented at the 60th Annual Meeting of the American Academy of Neurology (Chicago, IL).

Mickes L, Jacobson MW, Peavy GM, Goldstein JL, Lessig S, Loc K, Johnson EM, Corey-Bloom J (2008).  Screening For Cognitive Impairment in Huntington’s Disease (HD) Using Two Brief Measures.  Presented at the 12th International Congress of Parkinson’s Disease and Movement Disorders (Chicago, IL).

Pirogovsky E, J Goldstein, G Peavy, M Jacobson,  R Kim, J Corey-Bloom, P Gilbert. (2008). Memory for Temporal Order in Presymptomatic Gene Carriers for Huntington’s Disease. Presented at International Neuropsychological Society (Hawaii).

Davis, J.D., Filoteo, J.V., & Kesner, R.P. (2007).  Is short-term memory for discrete arm movements impaired in Huntington's disease?  Cortex, 43, 255-263.

Fennema-Notestine, C., Archibald, S.L., Jacobson, M.W., Lee, J.C., Peavy, G.M., Goldstein, J.L., Salmon, D.P., and Corey-Bloom, J.  (2007).  Structural correlates of BOLD effects in individuals at risk for Huntington’s disease.  Program No. 51.22. 2007 Abstract Viewer/Itinerary Planner. San Diego, CA: Society for Neuroscience. Online.

Kane AE, G.M. Peavy, J.L. Goldstein, M.W. Jacobson, S. Lessig, L. Wasserman, J. Corey-Bloom. (2007). Predictive value of CAG repeat length for age of HD onset: Differences between Hispanics and Caucasians. Presented at the World Congress on Huntington’s Disease, Dresden, Germany.

Kane AE, G. Peavy GM, Goldstein JL, Jacobson MW, Wasserman L, & Corey-Bloom J (2007). Are Demographic and Clinical Factors Potential Modulators of Age of Onset in Huntington¹s Disease? Presented at the American Academy of Neurology, Boston, MA, 2007.

Kane AE, Peavy, GM, Goldstein, JL, Jacobson, MW, Wasserman, LM, & Corey-Bloom J (2007). Do Demographics and clinical factors modulate age of onset in Huntington's disease? Neurology, 68, A229.

Peavy GM & Corey-Bloom, J. (2007). Cognitive deficits and dementia in Huntington's disease.  In B. Leavitt (Ed.), Huntington's Dementia. Carma Publishing, in press.

Peavy GM, MW Jacobson, AE Kane, JL Goldstein, L Mickes, S Lessig, J Lee, and J Corey-Bloom. (2007). Proposed criteria for the diagnosis of dementia associated with Huntington’s Disease (HD). Presented at the Inaugural Huntington’s Disease Clinical Research Symposium. Boston, MA.

Pirogovsky, E., Gilbert, P., Jacobson, M., Peavy, G., Wetter, S., Goldstein, J., Corey-Bloom, J.,
& Murphy, C. (2007). Impairments in source memory for olfactory and visual stimuli in pre-clinical and clinical stages of Huntington's disease. Journal of Clinical and Experimental Neuropsychology, 29(4), 395-404.

Turner TH, Goldstein J, Hamilton J, Jacobson M, Pirogovsky E, Peavy G, & Corey-Bloom J (2007). Behavioral saccade measures offer utility as biomarkers in Huntington's disease. Neurology, 68, A365.

Pirogovsky, E., Gilbert, P., Jacobson, M., Peavy, G., Wetter, S., Goldstein, J., Corey-Bloom, J., & Murphy, C. (2007) Impairments in source memory for olfactory and visual stimuli in pre-clinical and clinical stages of Huntington’s disease. Journal of Clinical and Experimental Neuropsychology, 29(4), 395-404.

Salmon, D. P., Filoteo, J. V., Possin, K. L., DiToro, B., & Galasko, D. (2007). Modality-Specific Patterns of Working Memory Impairment in Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease with Dementia. Submitted to the International Conference on Alzheimer`s and Parkinson`s Diseases, Salzburg, Austria.

Schiehser, D.M., Possin, K.L., Feffer, L.B., Salmon, D.P., Delis, D.C., Song, D.D., Corey-Bloom, J., Peavy, G., Filoteo, J.V. (2007). Retrieval Deficits in Patients with Parkinson's disease or Huntington's disease.  Presented at the 35th annual meeting of the International Neuropsychological Society, February, 2007, Portland, Oregon.

Wasserman L, Cahill T, Johnson D, Goldstein J, Peavy G, Jacobson MW, Corey-Bloom J (2007).  Genetic testing for the huntingtin gene CAG repeat using DNA collected from buccal swabs.  HD Clinical Research Symposium (Boston, MA).

Hamilton, J.M., Peavy, G., Jacobson, M.W., Goldstein, J.L., & Corey-Bloom, J. (2006). Dissociations in the relationship between apathy and cognition in Huntington's disease and Alzheimer's disease, Neurology, 66, A367.

Pirogovsky, E., Rice, J., Vallejo, F., Mekrut, A., Morris, A.M., Gilbert, P.E., Jacobson, M., Peavy, G., Wetter, S., Goldstein, J., Corey-Bloom, J., & Murphy, C. Impairments in source memory for olfactory and visual stimuli in preclinical and clinical stages of Huntington's disease. Presented at the annual meeting of the International Neuropsychological Society, February, 2006, Boston.

Possin, K. L., Cagigas, X. E., Strayer, D. L., & Filoteo, J. V. (2006). Lack of impairment in patients with Parkinson’s disease on an object-based negative priming task. Perceptual and Motor Skills, 102(1), 219-230.

Turner TH, Jody L. Goldstein, Joanne M. Hamilton, Mark W. Jacobson, Eva Pirogovsky, and Jody Corey-Bloom. Behavioral Testing of Saccadic Eye Movements in Huntington’s Disease. Presented at the annual meeting of the American Neurological Association in Chicago, Illinois, 2006

Peavy, G.M., Wetter, S.R., Hamilton, J.M., Jacobson, M.W., Goldstein, J.L., & Corey-Bloom, J. (2005). Proposed criteria for dementia in patients with Huntington's disease. Neurology, 62, A91-92.
 
Wetter, S.R., Peavy, G., Goldstein, J., Wasserman, L., Hamilton, J., Jacobson, M.W., Cahill, T., & Corey-Bloom, J. (2005). At risk for Huntington's disease (HD): The experience of a multi-disciplinary predictive testing center. Neurology, 64, A90-91.

Peavy, G.M., Wetter, S.R., Hamilton, J.M., Jacobson, M.W., Goldstein, J.L., Gamst, A.C. & Corey-Bloom, J. (2005).  Proposed criteria for dementia in patients with Huntington's disease. Movement Disorders, 20, 1239.

Hamilton, J.M., Corey-Bloom, J., Wolfson, T., Jacobson, M.W., Wetter, S.R., Goldstein, J.L., & Peavy, G.M. (2005). Progression of global cognitive decline in Huntington's disease. Neurology, 64 (Suppl 1):A91.

Delis, D.C., Wetter, S.R., Jacobson, M.W., Peavy, G., Hamilton, J., Gongvatana, A., Kramer, J.H., Bondi, M.W., Corey-Bloom, J., & Salmon, D.P. (2005). Recall Discriminability: Utility of a new CVLT-II measure in the differential diagnosis of dementia, Journal of the International Neuropsychological Society, 11, 708-715.

Jacobson, M.W., Delis DC, Hamilton JM, Bondi MW, Salmon DP. (2005) How do neuropsychologists define cognitive constructs? Further thoughts on limitations of factor analysis used with normal or mixed clinical populations. Journal of the International Neuropsychological Society 10, 7 1020-21.

Zizak, V.S., Filoteo V., Possin, K.L., Salmon, D.P., Lucas, J.A., Rilling, L.M., Davis, J.D., Peavy, G., & Wong, A. (2005). The ubiquity of memory retrieval deficits in patients with frontal-striatal dysfunction. Cognitive and Behavioral Neurology, 18, 198-205.

Pirogovsky, E., Rice, J., Vallejo, F., Mekrut, A., Siragusa, A.R., Morris, A.M., Gilbert, P.E., Jacobson, M., Peavy, G., Wetter, S., Goldstein, J., Corey-Bloom, J., & Murphy, C (2005). Deficits in source memory for olfactory and visual stimuli in Huntington's disease. Presented at the Annual Meeting of the Society for Neurosciences (Washington DC).

Lineweaver T, Salmon D, Bondi MW, Corey-Bloom J. (2005). Differential effects of Alzheimer’s disease and Huntington’s disease on the performance of mental rotation. J Int Soc, 11(1):30-39.

Wetter, S.G., Peavy, G.M., Jacobson, M.W., Hamilton, J.M., Salmon, D., & Murphy, C. (2005). Olfactory and auditory event-related potentials in Huntington's disease. (2005). Neuropsychology, 19, 428-436.

Hamilton JM, Wolfson T, Peavy G, Jacobson M, Corey-Bloom J, Group HS. (2004). Rate and correlated of weight weight change in Huntington’s disease. J Neurol Neurosurg Psychiatry, 75(2):209-212 

Fennema-Notestine C, Archibald S, Jacobson M, Corey-Bloom J, Paulsen J, Peavy G, Bamst A, Hamilton JM, Salmon D, Jernigan T. (2004). In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington’s disease. Neurology 63(6):989-995.

Fennema-Notestine C., Archibald S.L., Jacobson, M.W., Corey-Bloom J, Peavy G, Gamst A, Hamilton J, Paulsen JM, Salmon DP, Jernigan T. (2004).  In Vivo Evidence of cerebellar atrophy and cerebral white matter loss in Huntington’s disease. Neurology, 58, 989-995.
 
Fennema-Notestine C, Jacobson, MW, Archibald SL, Julaton MD, Levine, CM, Reyes, JPM, Peavy GM, Hamilton JM, Salmon DP, Corey-Bloom J. (2004) Complexity-related effects during an fMRI motor paradigm in individuals at risk for Huntington’s disease. Program No. 1016.16 . 2004 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience. Online.

Hamilton, J.M., Wolfson, T., Peavy, G.M., Jacobson, M.W., Corey-Bloom, JC. (2004). Rate and correlates of weight change in Huntington’s disease. Journal of Neurology, Neurosurgery, and Psychiatry 75: 209-212

Corey-Bloom J, Tiraboschi P, Kung JT, Peavy GM, Jacobson MW, Hamilton JM, & Goldstein J. (2004). A placebo-controlled pilot study of Donepezil in Huntington's disease (HD). Neurology, 62, A203.

Aron AR, Sahakian BJ, Robbins TW (2003a) Distractibility during selection-for-action: differential deficits in Huntington's disease and following frontal lobe damage. Neuropsychologia 41:1137-1147.

Aron AR, Watkins L, Sahakian BJ, Monsell S, Barker RA, Robbins TW (2003b) Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J Cogn Neurosci 15:629-642.

Aron AR, Schlaghecken F, Fletcher PC, Bullmore ET, Eimer M, Barker R, Sahakian BJ, Robbins TW (2003c) Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington's disease. Brain 126:713-723.

Davis, J. D., Filoteo, J. V., Kesner, R. P., & Roberts, J. W.  (2003).  Memory for motor-based information and spatial locations in patients with Huntington’s disease. Cortex, 39, 239-253.

Delis, D.C., Jacobson, M.W., Bondi, M.W., Hamilton, J.M., & Salmon, D.P. (2003). The myth of construct validity using factor analysis or correlations with normal or mixed clinical populations: Lessons from memory assessment. Journal of the International Neuropsychological Society, 9; 936-46.

Fennema-Notestine, C., Jacobson, M.W., Archibald, S.L., Julaton, M.D., Peavy, G.M.,  Hamilton, J.M., Salmon, D.P., Jernigan, T.L., & Corey-Bloom, J. (2003). Motor-related functional MRI abnormalities in individuals genetically at risk for Huntington's disease. Neurology, 60, A246.

Fennema-Notestine, C., Jacobson, M.W., Archibald, S.L., Julaton, M. D., Peavy, G.M., Hamilton, J.M., Salmon, D.P., Jernigan, T.L., Corey-Bloom, J. (2003). Motor-related functional MRI abnormalities in individuals genetically at-risk for Huntington’s disease. Neurology, 60 (5 Sup 1).

JM Hamilton, DP Salmon, J Corey-Bloom, A Gamst, JS Paulsen, S Jerkins, MW Jacobson, G Peavy.  (2003).  Behavioral abnormalities contribute to functional decline in Huntington’s disease.  J Neurol Neurosurg Psychiatry 74(1): 120-122.

Mahant N, McCusker EA, Buth K, Graham S, & The Huntington Study Group (2003)  Huntington’s disease:  Clinical correlates of disability and progression.  Neurology, 61, 1085-1092.

Peavy, G.M., Jacobson, M., Hamilton, J.M., Sepp, A., & Corey-Bloom, J. (2003). The Effects of Huperzine A on Cognitive Functioning and Behavior in Patients with Huntington’s Disease. Annals of Neurology, 54, S42.

Wetter, S., Peavy,  G., Jacobson, M., Hamilton, J., Salmon, D., & Murphy, C. (2003) Olfactory event-related potentials in Huntington’s disease. Journal of the International Neuropsychological Society, 9, 163-164.

Davis, J.D., Filoteo, J.V., Fargo, J., & Kesner, R.P.  "Object-location memory in Huntington's disease:  Examination of encoding, retention, and recognition processes".  Paper presented at the annual meeting of the International Neuropsychological Society, Toronto, 2002.

Fennema-Notestine, C., Archibald, S.L., Jacobson, M.W., Peavy, G.M., Julaton, M.D., Hamilton, J.M., Salmon, D.P., Corey-Bloom, J., Jernigan, T.L. (2002). Preliminary findings of white matter changes in people genetically at-risk for Huntington's Disease. Neurology, 58 (Suppl 3), A308.

Fennema-Notestine, C., Archibald, S.L., Jacobson, M.W., Peavy, G.M., Julaton, M.D., Hamilton, J.M., Salmon, D.P., Corey-Bloom, J., Jernigan, T.L. (2002). Subcortical and white matter volume differences in people genetically at risk for Huntington’s disease. Huntington’s Disease Society of America (HDSA) Coalition for the Cure Research Conference, April 26-28, Chicago, IL.

Fennema-Notestine C., Jacobson, M.W., Archibald, S.L., Peavy, G.M.,  Julaton, M., Hamilton, J.M., Salmon, D.P., Corey-Bloom, J., & Jernigan, T.L. (2002).  Preliminary findings of white matter changes in people genetically at risk for Huntington's disease. Neurology, 58, A308-309.

Fennema-Notestine, C. Archibald, S., Jacobson, M.W., Peavy, G., Julaton, M., Hamilton, J., Salmon, P., Corey-Bloom, G., Jernigan, T. (2002, April)  Preliminary findings of white matter changes in people genetically at risk for Huntington’s Disease. Presentation at American Academy of Neurology.

Hamilton, J.M. Corey-Bloom, J., Thomas, R.G., Peavy, G., Jacobson, M.W., & the Huntington’s Study Group. (2002). Correlates of weight change in Huntington’s disease. Neurology, 58, A309-310.

Hamilton, J., Corey-Bloom, J., Thomas, R., Peavy, G., Jacobson, M. (April 2002). Correlates of weight change in Huntington’s Disease. Presentation at American Academy of Neurology.

Peavy G, Salmon D, Jacobson M, Hamilton J, Corey-Bloom J. (2002). A comparison of dementia prevalence in Huntington’s disease as assessed by clinical impression and established criteria. Neurology 58 (A309)

Filoteo, J.V., Maddox, W.T., & Davis, J. D.  (2001).  A possible role of the striatum in linear and nonlinear category learning:  Evidence from patients with Huntington’s disease. Behavioral Neuroscience, 115, 786-798.

Golden, K., Peavy, G., Jacobson, M., Jerkins, S., Corey-Bloom, J. (2001) The Validity of the Odd-Man Out Test in patients with Huntington’s Disease. Journal of the International Neuropsychological Society, 7; 2, 128.

Golden, K., Peavy, G., Jacobson, M., Jerkins, S. & Corey-Bloom, J. (2001). The validity of the Odd-Man Out Test in patients with Huntington's disease. Journal of the International Neuropsychological Society, 7, 128.

GM Peavy, L Wilson, MW Jacobson, JM Hamilton, SM Jerkins, J Corey-Bloom. (2001).  Psychiatric symptoms as a function of Huntington’s disease diagnosis.  Neurology 56: A22-23

Hamilton, J., Salmon, D.P., Corey-Bloom, J., Jerkins, S., Paulsen, J.S., & Peavy, G. (2001). Behavioral ratings predict functional decline in Huntington's disease. Journal of the International Neuropsychological Society, 7, 215.

S Jerkins, M Jacobson, D Salmon, D Delis, G Peavy, K Golden, J Corey-Bloom.  (2001).  Source memory deficits in patients with Huntington’s disease and Alzheimer’s disease.  Journal of the International Neuropsychological Society 7: 128.

Jacobson M, Salmon D, Golden K, Paulsen J, Corey-Bloom J & Peavy G.  (2000).  Verbal learning and fluency in non-demented patients with Huntington's disease and Alzheimer's disease.  Journal of the International Neuropsychological Society  6: 209.

MW Jacobson, GM Peavy, DC Delis, SM Jerkins, KR Golden, DP Salmon, J Corey-Bloom. (2000).  The relationship between attention, working memory, and delayed memory in patients with Huntington’s disease (HD) and Alzheimer’s disease (AD). Neurology  54: A115-116. 

C Fennema-Notestine, SL Archibald, J Corey-Bloom, S Eberson-Shumate, JS Paulsen, G Peavy, TL Jernigan. (2000). Global pattern of neuroanatomical changes in Huntington’s disease with morphometric analyses of structural magnetic resonance imaging.  Neurology  54: A152-153.